Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
First Claim
1. A substantially monodispersed mixture of conjugates, each conjugate comprising a drug coupled to an oligomer that comprises a polyalkylene glycol moiety.
3 Assignments
0 Petitions
Accused Products
Abstract
A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may result in less inter-subject variability than polydispersed mixtures of similar conjugates.
-
Citations
103 Claims
- 1. A substantially monodispersed mixture of conjugates, each conjugate comprising a drug coupled to an oligomer that comprises a polyalkylene glycol moiety.
- 54. A mixture of conjugates each comprising a drug coupled to an oligomer that comprises a polyalkylene glycol moiety, said mixture having a molecular weight distribution with a standard deviation of less than about 22 Daltons.
- 65. A mixture of conjugates each comprising a drug coupled to a polymer comprising a polyalkylene glycol moiety, wherein the mixture has a dispersity coefficient (DC) greater than 10,000 where
-
76. A mixture of conjugates in which each conjugate:
-
comprises a drug coupled to an oligomer; and
has the same number of polyalkylene glycol subunits. - View Dependent Claims (77, 78, 79, 80, 81, 82, 83, 84)
-
- 85. A mixture of conjugates in which each conjugate has the same molecular weight and has the formula:
-
95. A process for synthesizing a substantially monodispersed mixture of conjugates each conjugate comprising a drug coupled to an oligomer that comprises a polyethylene glycol moiety, said process comprising:
-
reacting a substantially monodispersed mixture comprising compounds having the structure of Formula I;
R1(OC2H4)m—
O−
X+
(I)wherein R1 is H or a lipophilic moiety;
m is from 1 to 25; and
X+ is a positive ion,with a substantially monodispersed mixture comprising compounds having the structure of Formula II;
R2(OC2H4)n—
OMs
(II)wherein R2 is H or a lipophilic moiety; and
n is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture comprising polymers having the structure of Formula III;
R2(OC2H4)m+n—
OR1
(III);
activating the substantially monodispersed mixture comprising polymers of Formula III to provide a substantially monodispersed mixture of activated polymers capable of reacting with a drug; and
reacting the substantially monodispersed mixture of activated polymers with a substantially monodispersed mixture of drugs under conditions sufficient to provide a substantially monodispersed mixture of conjugates each comprising a drug coupled to an oligomer that comprises a polyethylene glycol moiety with m+n subunits. - View Dependent Claims (96, 97, 98, 99, 100, 101, 102, 103)
-
Specification